Radius Health Announces Positive Top-line Data From Phase 3 ACTIVE Trial

(RTTNews) - Radius Health, Inc. (RDUS) announces positive top-line data from Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial.

The results showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo.

Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide at 6, 12 and 18 months.

These results, along with positive pharmacokinetic data from a study evaluating the ABL transdermal patch, were presented during the American Society for Bone and Mineral Research 2015 Annual Meeting as oral and poster presentations, respectively.

"The Phase 3 ACTIVE trial found that women who were taking abaloparatide experienced an early risk reduction for major osteoporotic fractures," said Dr. Lorraine Fitzpatrick, Chief Medical Officer at Radius Health. "

ACTIVE is a randomized, double-blind, placebo controlled Phase 3 trial evaluating fracture prevention in more than 2,400 women suffering from PMO.